Related Experiment Video
Updated: Jun 30, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
MBNL1-mediated alternative splicing in cancer: underlying mechanism, isoform regulation, and translational
Huidan Tan1, Rongyan Zhao1, Bo Liu1
1Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
Alternative splicing (AS) is a major mechanism that expands proteomic diversity and fine-tunes gene expression in eukaryotic cells. Its dysregulation is now recognized as a hallmark of cancer and contributes to tumor initiation, progression, metastasis, and therapeutic resistance. Muscleblind-like splicing regulator 1 (MBNL1) is a highly conserved RNA-binding protein (RBP) that controls AS, RNA stability, and other aspects of transcript processing. Increasing evidence indicates that MBNL1 expression, isoform composition, and subcellular localization are frequently altered in multiple cancer types. Through these changes, MBNL1 reshapes the splicing programs of cancer-related genes and exerts context-dependent tumor-suppressive or tumor-supportive effects. This review summarizes the structure and biological functions of MBNL1, the major mechanisms through which it regulates cancer-associated AS, its expression and isoform-specific features across different tumor types, and emerging therapeutic strategies targeting MBNL1 and its downstream splicing network. Current challenges and future directions are also discussed. Overall, MBNL1 represents a promising splicing regulator with potential value for biomarker development and precision cancer therapy.
Insights
Alternative splicing (AS) dysregulation is key in cancer. Muscleblind-like splicing regulator 1 (MBNL1) alters cancer-related gene splicing, showing potential for cancer biomarkers and therapies.
Area of Science:
- Molecular Biology
- Cancer Biology
- RNA Biology
Background:
- Alternative splicing (AS) expands proteomic diversity but its dysregulation is a cancer hallmark.
- Muscleblind-like splicing regulator 1 (MBNL1), an RNA-binding protein, controls AS and transcript processing.
- Altered MBNL1 expression and localization are observed in various cancer types.
Purpose of the Study:
- To review MBNL1's role in cancer-associated AS.
- To summarize MBNL1's mechanisms, expression, and therapeutic potential in cancer.
- To discuss challenges and future directions for MBNL1-targeted cancer therapy.
Main Methods:
- Literature review of MBNL1's function in cancer.
- Analysis of MBNL1's impact on cancer-related gene splicing.
- Examination of MBNL1 expression patterns and isoform-specific features in tumors.
Main Results:
- MBNL1 reshapes splicing programs of cancer-related genes.
- MBNL1 exhibits context-dependent tumor-suppressive or tumor-supportive roles.
- MBNL1 alterations are frequent in multiple cancer types, influencing progression and resistance.
Conclusions:
- MBNL1 is a crucial regulator of cancer-associated AS.
- MBNL1 holds promise for biomarker development and precision cancer therapy.
- Targeting MBNL1 and its splicing network offers new therapeutic strategies.
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...

